Kevin R. Regner, MD, MS, FASN

Publications

• Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1.

  (Velez JCQ, Karakala N, Tayebi K, Wickman TJ, Mohamed MMB, Kovacic RA, Therapondos G, Kanduri SR, Allegretti AS, Belcher JM, Regner KR, Wentowski C.) Kidney360. 2023 Apr 01;4(4):e448-e456 PMID: 36763632 02/11/2023

• Cannabinoid Type 2 Receptor Activation Reduces the Progression of Kidney Fibrosis Using a Mouse Model of Unilateral Ureteral Obstruction.

  (Swanson ML, Regner KR, Moore BM 2nd, Park F.) Cannabis Cannabinoid Res. 2022 Dec;7(6):790-803 PMID: 35196117 SCOPUS ID: 2-s2.0-85147378966 02/24/2022

• p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat

  (Miller B, Regner K, Sorokin A.) Biochemical and Biophysical Research Communications. 7 May 2022;603:69-74 SCOPUS ID: 2-s2.0-85125835040 05/07/2022

• p66Shc signaling does not contribute to tubular damage induced by renal ischemia-reperfusion injury in rat.

  (Miller B, Regner K, Sorokin A.) Biochem Biophys Res Commun. 2022 May 07;603:69-74 PMID: 35278882 PMCID: PMC8969123 SCOPUS ID: 2-s2.0-85125835040 03/13/2022

• Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.

  (Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, HRS-HARMONY Study Investigators.) Am J Kidney Dis. 2022 May;79(5):737-745 PMID: 34606933 SCOPUS ID: 2-s2.0-85122545748 10/05/2021

• Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions.

  (Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M.) Kidney Int. 2022 Apr;101(4):766-778 PMID: 35114200 PMCID: PMC8940673 SCOPUS ID: 2-s2.0-85125312317 02/04/2022

• DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity.

  (Hama T, Nagesh PK, Chowdhury P, Moore BM 2nd, Yallapu MM, Regner KR, Park F.) JCI Insight. 2021 Nov 22;6(22) PMID: 34806647 PMCID: PMC8663775 SCOPUS ID: 2-s2.0-85120382452 11/23/2021

• Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study.

  (Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, Kalim S, Nigwekar SU, Flood JG, Nixon A, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Regner KR, Belcher JM, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, HRS-HARMONY study investigators.) Clin Transl Gastroenterol. 2021 May 11;12(5):e00359 PMID: 33979307 PMCID: PMC8116001 SCOPUS ID: 2-s2.0-85105838703 05/13/2021

• AKI in Hospitalized Patients with COVID-19 and Seasonal Influenza: A Comparative Analysis.

  (Bhasin B, Veitla V, Dawson AZ, Garacci Z, Sturgill D, Ozieh MN, Regner KR.) Kidney360. 2021 Apr 29;2(4):619-628 PMID: 35373047 PMCID: PMC8791326 02/26/2021

• Patients with Hepatorenal Syndrome Should Be Dialyzed? COMMENTARY.

  (Regner KR.) Kidney360. 2021 Mar 25;2(3):413-414 PMID: 35378024 PMCID: PMC8786001 12/16/2020

• DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity

  (Hama T, Nagesh PKB, Chowdhury P, Moore BM, Yallapu MM, Regner KR, Park F.) JCI Insight. 22 November 2021;6(22) SCOPUS ID: 2-s2.0-85120382452 11/22/2021

• Endogenous miR-204 Protects the Kidney against Chronic Injury in Hypertension and Diabetes.

  (Cheng Y, Wang D, Wang F, Liu J, Huang B, Baker MA, Yin J, Wu R, Liu X, Regner KR, Usa K, Liu Y, Zhang C, Dong L, Geurts AM, Wang N, Miller SS, He Y, Liang M.) J Am Soc Nephrol. 2020 Jul;31(7):1539-1554 PMID: 32487559 PMCID: PMC7350998 SCOPUS ID: 2-s2.0-85087468924 06/04/2020